Literature DB >> 18038392

Multipotent adult progenitor cell transplantation increases vascularity and improves left ventricular function after myocardial infarction.

Beatriz Pelacho1, Yasuhiro Nakamura, Jianyi Zhang, Jeff Ross, Yves Heremans, Molly Nelson-Holte, Brad Lemke, Julianna Hagenbrock, Yuehua Jiang, Felipe Prosper, Aernout Luttun, Catherine M Verfaillie.   

Abstract

Progressive contractile dysfunction of viable myocardium that surrounds a large infarct leads to heart failure following acute myocardial infarction (AMI). Experimental evidence indicates that cellular transplantation may improve the left ventricular (LV) contractile performance, even though the underlying mechanisms remain undefined. Here, we compared the effect of transplantation of murine multipotent adult progenitor cells (MAPCs), a population of adult bone marrow-derived cells that differentiate into cells of mesodermal, endodermal and ectodermal origin, with murine bone marrow cells (BMCs) or fibroblasts on post-infarct cardiac function by peri-infarct injection after coronary artery ligation in mice. We demonstrate that, in contrast to the other cell populations, transplantation of MAPCs significantly improved LV contractile function for at least 8 weeks post-transplantation and, although BMCs reduced infarct size, the decrease in scar size was substantially greater in MAPC-treated hearts. As neither MAPCs nor BMCs were present beyond 1 week, the beneficial effect was not due to differentiation and direct contribution of MAPCs to the vascular or cardiomyocyte compartment. Significantly more inflammatory cells were present in MAPC- than BMC-treated hearts at 1 week, which was accompanied by increased vascularity 8 weeks post-transplantation. We hypothesize that MAPCs indirectly contributed to these effects, by secreting inflammatory [monocyte chemoattractant protein-1 (MCP)-1], and vascular growth factors [vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-BB, and transforming growth factor (TGF)beta(1)), and others, resulting in increased angiogenensis and cardioprotection. 2007 John Wiley & Sons, Ltd

Entities:  

Mesh:

Year:  2007        PMID: 18038392     DOI: 10.1002/term.7

Source DB:  PubMed          Journal:  J Tissue Eng Regen Med        ISSN: 1932-6254            Impact factor:   3.963


  19 in total

Review 1.  Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.

Authors:  James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

2.  Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression.

Authors:  Elke Eggenhofer; Felix C Popp; Michael Mendicino; Paula Silber; Wouter Van't Hof; Philipp Renner; Martin J Hoogduijn; Jef Pinxteren; Nico van Rooijen; Edward K Geissler; Robert Deans; Hans J Schlitt; Marc H Dahlke
Journal:  Stem Cells Transl Med       Date:  2013-07-08       Impact factor: 6.940

3.  Inhibition of DNA methyltransferases and histone deacetylases induces bone marrow-derived multipotent adult progenitor cells to differentiate into endothelial cells.

Authors:  Saswati Mahapatra; Meri T Firpo; Methode Bacanamwo
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

4.  The Structural Basis of Functional Improvement in Response to Human Umbilical Cord Blood Stem Cell Transplantation in Hearts With Postinfarct LV Remodeling.

Authors:  Yong Chen; Lei Ye; Jia Zhong; Xin Li; Chen Yan; Margaret P Chandler; Steve Calvin; Feng Xiao; Mesfin Negia; Walter C Low; Jianyi Zhang; Xin Yu
Journal:  Cell Transplant       Date:  2013-12-10       Impact factor: 4.064

5.  Neuregulin-1β induces mature ventricular cardiac differentiation from induced pluripotent stem cells contributing to cardiac tissue repair.

Authors:  Olalla Iglesias-García; Sven Baumgartner; Laura Macrí-Pellizzeri; Juan Roberto Rodriguez-Madoz; Gloria Abizanda; Elizabeth Guruceaga; Edurne Albiasu; David Corbacho; Carolina Benavides-Vallve; Mario Soriano-Navarro; Susana González-Granero; Juan José Gavira; Benjamin Krausgrill; Moises Rodriguez-Mañero; Jose Manuel García-Verdugo; Carlos Ortiz-de-Solorzano; Marcel Halbach; Juergen Hescheler; Beatriz Pelacho; Felipe Prósper
Journal:  Stem Cells Dev       Date:  2014-11-25       Impact factor: 3.272

Review 6.  Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue.

Authors:  Maritza Mayorga; Amanda Finan; Marc Penn
Journal:  Stem Cell Rev Rep       Date:  2009-01-30       Impact factor: 5.739

7.  Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming.

Authors:  Steven L Highfill; Ryan M Kelly; Matthew J O'Shaughnessy; Qing Zhou; Lily Xia; Angela Panoskaltsis-Mortari; Patricia A Taylor; Jakub Tolar; Bruce R Blazar
Journal:  Blood       Date:  2009-05-20       Impact factor: 22.113

Review 8.  Cell therapy with bone marrow cells for myocardial regeneration.

Authors:  Hyongbum Kim; Sung-Whan Kim; Douglas Nam; Sinae Kim; Young-Sup Yoon
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

9.  Increased angiogenesis and improved left ventricular function after transplantation of myoblasts lacking the MyoD gene into infarcted myocardium.

Authors:  Yasuhiro Nakamura; Yoko Asakura; Bryan A Piras; Hiroyuki Hirai; Christopher T Tastad; Mayank Verma; Amanda J Christ; Jianyi Zhang; Takanori Yamazaki; Minoru Yoshiyama; Atsushi Asakura
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice.

Authors:  Silvia Mora-Lee; Ma Salomé Sirerol-Piquer; María Gutiérrez-Pérez; Ulises Gomez-Pinedo; Valerie D Roobrouck; Tania López; Mayte Casado-Nieto; Gloria Abizanda; Maria Teresa Rabena; Catherine Verfaille; Felipe Prósper; Jose Manuel García-Verdugo
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.